Hunan Huateng Pharmaceutical Co. Ltd. news

Hunan Huateng Pharmaceutical Co., Ltd. is excited to announce the availability of three high-quality cosmetic ingredients now in stock and ready for immediate delivery. These trusted actives are ideal for formulations in skin brightening, dandruff control, and sun protection.

Now Available:

Diethylamino Hydroxybenzoyl Hexyl Benzoate (CAS No. 302776-68-7)

A high-efficiency UVA filter with REACH Registration, delivering long-lasting protection against UV-induced skin agi

Versatile compound shows promise in drug synthesis, metal chelation, antioxidant activity, and more

Changsha, China – May 22, 2025– Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical developers worldwide. This compound has gained attention for its multifunctional properties and critical role in drug d

Changsha, China – 18 March 2025 – Hunan Huateng Pharmaceutical Co., Ltd., a global leader in PEG derivatives and CDMO services for APIs and intermediates, is pleased to announce its participation in CPHI Japan 2025. The company will exhibit its comprehensive product lines and cutting-edge capabilities at Booth No. 4X-06, located at Tokyo Big Sight, Tokyo, Japan, from April 9th to 11th, 2025.

Huateng Pharma is dedicated to providing robust support to the biopharmaceutic

Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. (Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. This achievement highlights Huateng Pharma’s dedication to meeting the highest regulatory standards and further strengthens its commitment to supp

Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. is proud to provide high-quality monodispersed polyethylene glycols (PEGs) tailored for the evolving needs of antibody-drug conjugates (ADCs). With the ADC market surpassing $10 billion in 2023 and projected to reach $13.13 billion by 2030, our commitment to innovation and quality is stronger than ever.

Among the 15 approved ADCs globally, notable therapies like Trodelvy

Huateng Pharma, a leading supplier of PEG derivatives and trusted CDMO partner, is thrilled to announce its participation in CPhI Worldwide 2024, scheduled for October 14-16 in Milan, Italy. Attendees are encouraged to visit booth #3F81, where the Huateng team will present its innovative capabilities in GMP-grade PEG derivative production, Contract Development and Manufacturing Organization (CDMO) services, and fine chemicals.

Sonia Lee, Business Development Manager at Huateng Pharma,

Huateng Pharma, a leading Contract Development and Manufacturing Organization (CDMO), is proud to announce its comprehensive range of services catering to Veterinary APIs, Pharmaceutical Intermediates, Cosmetic Ingredients, and Specialty & Fine Chemicals. With a steadfast commitment to innovation, quality, and customer satisfaction, Huateng Pharma continues to make significant strides in the pharmaceutical industry.

Huateng Pharma has positioned itself as a reliable partner for clie

Huateng Pharma, a global leader in PEG derivatives and a premier CDMO for APIs and intermediates, is excited to announce the launch of its latest product, Y-Shape PEG NHS. This cutting-edge Succinimidyl Carboxymethyl Ester branched 2ARM PEG offers a revolutionary approach to amine PEGylation, enhancing the modification of proteins and other biologics.

PEGylation, the technique of attaching a PEG derivative to molecules, is crucial for improving the water solubility an

Shanghai, China – June 14, 2024 – Hunan Huateng Pharmaceutical Co., Ltd., a global leader in the production of PEG derivatives and Contract Development and Manufacturing Organization (CDMO) services for Active Pharmaceutical Ingredients (APIs) and intermediates, is excited to announce its participation in CPHI China 2024. The event will take place from June 19 to 21, 2024, at the Shanghai New International Expo Center. Hunan Huateng Pharmaceutical will be located at Booth No. W3P16.